[{"id":"d4921ecb-dbf8-4a8b-a82b-331ac066876f","acronym":"ACHIEVE Study","url":"https://clinicaltrials.gov/study/NCT06096844","created_at":"2023-10-24T15:13:40.333Z","updated_at":"2025-02-25T12:38:45.622Z","phase":"Phase 3","brief_title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","source_id_and_acronym":"NCT06096844 - ACHIEVE Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-24"},{"id":"8b904991-7019-4cce-9e04-2e7482447f70","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815173","created_at":"2023-04-18T15:04:23.224Z","updated_at":"2025-02-25T14:09:36.744Z","phase":"Phase 1","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC","source_id_and_acronym":"NCT05815173","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-19"},{"id":"47dd1b32-326d-4c9b-9c8a-fd5502dd3a1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04181788","created_at":"2021-01-18T20:23:26.859Z","updated_at":"2025-02-25T14:07:35.999Z","phase":"Phase 2","brief_title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","source_id_and_acronym":"NCT04181788","lead_sponsor":"Pfizer","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zumrad (sasanlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 03/18/2020","start_date":" 03/18/2020","primary_txt":" Primary completion: 03/03/2022","primary_completion_date":" 03/03/2022","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-02-18"},{"id":"4d54d643-0fe9-4810-a13b-245e0370f07e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05840770","created_at":"2023-05-03T15:04:46.037Z","updated_at":"2025-02-25T14:09:39.987Z","phase":"Phase 2","brief_title":"Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 \u003e= 50% Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05840770","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 10/30/2029","primary_completion_date":" 10/30/2029","study_txt":" Completion: 10/30/2029","study_completion_date":" 10/30/2029","last_update_posted":"2025-02-18"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"8f37731b-089c-47c1-a812-0b453cccb247","acronym":"DENIVOS","url":"https://clinicaltrials.gov/study/NCT03669523","created_at":"2021-01-18T18:00:15.676Z","updated_at":"2025-02-25T15:10:56.744Z","phase":"Phase 2","brief_title":"Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS)","source_id_and_acronym":"NCT03669523 - DENIVOS","lead_sponsor":"Centre Hospitalier Annecy Genevois","biomarkers":" EGFR • PD-L1 • BRAF • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 11/06/2018","start_date":" 11/06/2018","primary_txt":" Primary completion: 10/19/2023","primary_completion_date":" 10/19/2023","study_txt":" Completion: 10/19/2023","study_completion_date":" 10/19/2023","last_update_posted":"2025-02-13"},{"id":"57381c24-31ec-4c63-b601-61888dd1102a","acronym":"EA5163","url":"https://clinicaltrials.gov/study/NCT03793179","created_at":"2021-01-18T18:45:20.609Z","updated_at":"2025-02-25T16:37:19.034Z","phase":"Phase 3","brief_title":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03793179 - EA5163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"0e159834-d55b-493f-b633-ada407fa2107","acronym":"KEYNOTE-603","url":"https://clinicaltrials.gov/study/NCT03313778","created_at":"2021-01-18T16:21:59.009Z","updated_at":"2025-02-25T16:07:00.519Z","phase":"Phase 1","brief_title":"Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors","source_id_and_acronym":"NCT03313778 - KEYNOTE-603","lead_sponsor":"ModernaTX, Inc.","biomarkers":" EGFR • ALK • TMB","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK translocation • EGFR positive","tags":["EGFR • ALK • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK translocation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)"],"overall_status":"Recruiting","enrollment":" Enrollment 242","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-22"},{"id":"db3994c6-3749-4a13-acb1-99aa40802cdb","acronym":"CORAL-Lung","url":"https://clinicaltrials.gov/study/NCT05000710","created_at":"2021-08-11T14:55:34.487Z","updated_at":"2025-02-25T15:00:02.742Z","phase":"Phase 2","brief_title":"Concomitant Radiotherapy, Tremelimumab \u0026 Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","source_id_and_acronym":"NCT05000710 - CORAL-Lung","lead_sponsor":"Sheba Medical Center","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK translocation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-05"},{"id":"97308bd2-983a-4c51-b306-4acc6a3f68ec","acronym":"KEYNOTE A60","url":"https://clinicaltrials.gov/study/NCT04332653","created_at":"2021-01-18T20:58:47.509Z","updated_at":"2025-02-25T16:10:08.704Z","phase":"Phase 1/2","brief_title":"NT-I7 (Efineptakin Alfa) in Combination with Pembrolizumab in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT04332653 - KEYNOTE A60","lead_sponsor":"NeoImmuneTech","biomarkers":" BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK translocation","tags":["BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hyleukin-7 (efineptakin alfa)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 06/10/2020","start_date":" 06/10/2020","primary_txt":" Primary completion: 11/05/2024","primary_completion_date":" 11/05/2024","study_txt":" Completion: 12/20/2024","study_completion_date":" 12/20/2024","last_update_posted":"2024-10-07"},{"id":"e0d150b0-e8da-41e4-9df7-1fc41df6dcb0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02484404","created_at":"2021-01-17T17:57:31.886Z","updated_at":"2024-07-02T16:34:36.994Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...","source_id_and_acronym":"NCT02484404","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2","pipe":" | ","alterations":" BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation","tags":["EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)"],"overall_status":"Recruiting","enrollment":" Enrollment 384","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-06-07"},{"id":"3ffb83b9-b7f6-4a1b-b219-82bb668c8ae7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03847519","created_at":"2021-01-18T18:59:33.778Z","updated_at":"2024-07-02T16:34:59.300Z","phase":"Phase 1/2","brief_title":"Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT03847519","lead_sponsor":"Advaxis, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • ALK translocation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • OST-503"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 02/22/2022","primary_completion_date":" 02/22/2022","study_txt":" Completion: 02/22/2022","study_completion_date":" 02/22/2022","last_update_posted":"2024-06-04"},{"id":"ef2ab7b8-a2e5-4df2-83fe-3e4e96f58f67","acronym":"","url":"https://clinicaltrials.gov/study/NCT04693468","created_at":"2021-01-19T20:49:06.628Z","updated_at":"2024-07-02T16:34:58.952Z","phase":"Phase 1","brief_title":"Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial","source_id_and_acronym":"NCT04693468","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D","pipe":" | ","alterations":" MET amplification • MET mutation • MET expression • ALK translocation","tags":["ALK • MET • BRCA1 • BRCA2 • ROS1 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET mutation • MET expression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Ibrance (palbociclib) • Talzenna (talazoparib) • axitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 111","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 09/03/2025","primary_completion_date":" 09/03/2025","study_txt":" Completion: 09/03/2025","study_completion_date":" 09/03/2025","last_update_posted":"2024-06-04"},{"id":"4523c8fb-2bb2-4827-ae8f-b3881f2e807b","acronym":"RG1005458","url":"https://clinicaltrials.gov/study/NCT04151940","created_at":"2021-01-18T20:14:53.791Z","updated_at":"2024-07-02T16:35:05.264Z","phase":"","brief_title":"PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04151940 - RG1005458","lead_sponsor":"University of Washington","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK translocation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/26/2019","start_date":" 09/26/2019","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-08"},{"id":"820e22ed-50fe-40f0-aa7c-051ded02330b","acronym":"CA209-117","url":"https://clinicaltrials.gov/study/NCT01928576","created_at":"2021-01-18T08:42:53.521Z","updated_at":"2025-02-25T14:34:17.894Z","phase":"Phase 2","brief_title":"Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.","source_id_and_acronym":"NCT01928576 - CA209-117","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" EGFR • KRAS • ALK","pipe":" | ","alterations":" EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation","tags":["EGFR • KRAS • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR exon 19 deletion • ALK positive • ALK rearrangement • EGFR wild-type • ALK wild-type • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine • Jingzhuda (entinostat) • Onureg (azacitidine oral)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 11/06/2013","start_date":" 11/06/2013","primary_txt":" Primary completion: 04/04/2023","primary_completion_date":" 04/04/2023","study_txt":" Completion: 04/04/2023","study_completion_date":" 04/04/2023","last_update_posted":"2024-05-03"},{"id":"6843c310-89f3-4a46-822e-007bc52f641b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420220","created_at":"2022-06-15T15:55:24.895Z","updated_at":"2024-07-02T16:35:06.663Z","phase":"Phase 2","brief_title":"Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05420220","lead_sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • erfonrilimab (KN046)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 07/15/2022","start_date":" 07/15/2022","primary_txt":" Primary completion: 05/29/2027","primary_completion_date":" 05/29/2027","study_txt":" Completion: 12/26/2027","study_completion_date":" 12/26/2027","last_update_posted":"2024-05-01"},{"id":"40e9c584-14da-4391-b55e-d2b5af41ff2b","acronym":"MK-1308-001","url":"https://clinicaltrials.gov/study/NCT03179436","created_at":"2021-01-17T17:28:19.740Z","updated_at":"2024-07-02T16:35:09.610Z","phase":"Phase 1/2","brief_title":"Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)","source_id_and_acronym":"NCT03179436 - MK-1308-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • BRAF • ALK • CTLA4","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • ALK translocation","tags":["EGFR • BRAF • ALK • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • quavonlimab (MK-1308) • quavonlimab/pembrolizumab (MK-1308A)"],"overall_status":"Completed","enrollment":" Enrollment 413","initiation":"Initiation: 07/02/2017","start_date":" 07/02/2017","primary_txt":" Primary completion: 04/08/2024","primary_completion_date":" 04/08/2024","study_txt":" Completion: 04/08/2024","study_completion_date":" 04/08/2024","last_update_posted":"2024-04-16"},{"id":"a4db82ac-25ea-4169-8bb8-cb613afd0358","acronym":"ATATcH","url":"https://clinicaltrials.gov/study/NCT05358548","created_at":"2022-05-03T14:53:59.407Z","updated_at":"2024-07-02T16:35:10.415Z","phase":"Phase 2","brief_title":"ATATcH Alternating Treatment Plans for Advanced Cancer","source_id_and_acronym":"NCT05358548 - ATATcH","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" EGFR • PD-L1 • BRAF • ALK • MET • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • MET exon 14 mutation • MET mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-10"},{"id":"5b0dcaae-cf24-41c0-a530-8101673f05e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815186","created_at":"2023-04-18T15:04:23.494Z","updated_at":"2024-07-02T16:35:12.309Z","phase":"Phase 2","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC - Phase II","source_id_and_acronym":"NCT05815186","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-29"},{"id":"5fbc8948-86a4-473a-8af0-ad784172a666","acronym":"","url":"https://clinicaltrials.gov/study/NCT02314364","created_at":"2021-01-18T10:57:47.929Z","updated_at":"2024-07-02T16:35:12.243Z","phase":"Phase 2","brief_title":"A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC","source_id_and_acronym":"NCT02314364","lead_sponsor":"Massachusetts General Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 11/10/2021","primary_completion_date":" 11/10/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-03-29"},{"id":"99da48d9-3c70-49ca-9c4f-caad6ae87340","acronym":"","url":"https://clinicaltrials.gov/study/NCT03099174","created_at":"2021-01-18T15:16:18.304Z","updated_at":"2024-07-02T16:35:16.312Z","phase":"Phase 1","brief_title":"This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.","source_id_and_acronym":"NCT03099174","lead_sponsor":"Boehringer Ingelheim","biomarkers":" HER-2 • ER • ALK • PGR","pipe":" | ","alterations":" EGFR mutation • HER-2 negative • ALK translocation","tags":["HER-2 • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 negative • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • xentuzumab (BI-836845)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 05/04/2017","start_date":" 05/04/2017","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 05/30/2024","study_completion_date":" 05/30/2024","last_update_posted":"2024-03-05"},{"id":"c14e2d3d-2408-48c9-8ec6-22c81595ada5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487095","created_at":"2021-01-18T11:59:05.036Z","updated_at":"2024-07-02T16:35:16.360Z","phase":"Phase 1/2","brief_title":"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers","source_id_and_acronym":"NCT02487095","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK translocation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • topotecan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/30/2015","start_date":" 07/30/2015","primary_txt":" Primary completion: 02/24/2021","primary_completion_date":" 02/24/2021","study_txt":" Completion: 10/30/2025","study_completion_date":" 10/30/2025","last_update_posted":"2024-03-05"},{"id":"ffa751f1-ed5d-4679-802a-6002b9595478","acronym":"","url":"https://clinicaltrials.gov/study/NCT02473497","created_at":"2021-01-18T11:54:26.767Z","updated_at":"2024-07-02T16:35:16.518Z","phase":"","brief_title":"Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients","source_id_and_acronym":"NCT02473497","lead_sponsor":"Pfizer","biomarkers":" ALK • MET • ROS1 • NTRK3 • ETV6","pipe":" | ","alterations":" NTRK3 fusion • ALK mutation • ETV6-NTRK3 fusion • ALK translocation","tags":["ALK • MET • ROS1 • NTRK3 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK3 fusion • ALK mutation • ETV6-NTRK3 fusion • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-04"},{"id":"44f9e1b3-6856-412b-91b0-43acf5d977c5","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT02034981","created_at":"2021-01-17T17:58:03.438Z","updated_at":"2024-07-02T16:35:17.368Z","phase":"Phase 2","brief_title":"Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1","source_id_and_acronym":"NCT02034981 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" ALK • MET • ROS1","pipe":" | ","alterations":" ALK positive • MET overexpression • ALK translocation","tags":["ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET overexpression • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib)"],"overall_status":"Completed","enrollment":" Enrollment 246","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-02-28"}]